Reporting on market developments concerning How Bristol Myers's CEO Challenged the Company's Managers. Industry analysts and investors are monitoring the operational, strategic, an...

Bristol Myers Squibb is defending its clinical pipeline after a patient death in an autoimmune trial, reassuring investors over its broader immunology strategy.

Bristol Myers Squibb has raised its annual financial outlook following stronger-than-expected quarterly revenue, driven by robust uptake in its growth portfolio.

GSK projects its oncology pipeline will nearly double next year, riding a wave of targeted acquisitions aimed at countering upcoming patent expirations.